Theory Paper IIDrNB Cardiology – Theory Notes

CARDIAC SEQUELAE OF KAWASAKI DISEASE AND MANAGEMENT

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IDEFINITION AND THREE-PROCESS CORONARY ARTERIOPATHY (AHA 2017 & 2024 UPDATE)

  • Definition: Kawasaki Disease (KD; mucocutaneous lymph node syndrome) is an acute, self-limited systemic vasculitis of medium-sized extraparenchymal muscular arteries occurring predominantly in infants and young children (80 percent under 5 years of age), with a specific predilection for the epicardial coronary arteries—making it the leading cause of acquired heart disease in children in developed nations and an increasingly recognized cause of premature adult CAD in India.
  • Three Linked Pathological Processes of Kawasaki Arteriopathy (Orenstein / AHA Model):
    • Acute Necrotizing Arteritis (Days 1 to 14 — Self-Limited): Synchronized neutrophilic infiltration starting from the luminal endothelium and progressing outward across the wall destroys the tunica media and internal and external elastic laminae via matrix metalloproteinases (MMP-9) and elastases, causing loss of structural integrity and saccular or fusiform Coronary Artery Aneurysms (CAAs) (and rare acute fatal coronary rupture within the first 2 to 3 weeks).
    • Subacute and Chronic Vasculitis (Weeks to Months/Years): Asynchronous infiltration of CD8+ cytotoxic T-lymphocytes, IgA plasma cells, eosinophils, and macrophages beginning in the adventitia/vasa vasorum and progressing inward.
    • Luminal Myofibroblastic Proliferation (LMP — Months to Decades): Smooth-muscle-derived myofibroblasts (stimulated by TGF-beta and PDGF) proliferate concentrically within the intima, accompanied by layered mural thrombosis and heavy dystrophic “eggshell” calcification—progressively narrowing the lumen (especially at the proximal entrance and distal exit of giant aneurysms) and causing late occlusive coronary stenosis and myocardial infarction in adolescence or young adulthood.

IICARDIAC SEQUELAE: VASCULAR, MYOCARDIAL, VALVULAR AND ELECTRICAL

  • Coronary Artery Aneurysms (CAAs — AHA Body Surface Area-Adjusted Z-Score Classification): Develop in 20 to 25 percent of untreated children (reduced to ~3 to 5 percent with timely IVIG therapy). Anatomic predilection sites: Proximal LAD > Proximal RCA > Left Main Coronary Artery (LMCA) > LCx > Distal RCA. Because absolute millimeter cut-offs (historical Japanese Ministry of Health criteria) systematically underdiagnosed aneurysms in infants, the AHA Z-Score Classification (standard deviations from normal BSA-adjusted mean) is mandatory:
AHA Z-Score Classification (McCrindle 2017 / Jone 2024) Coronary Internal Lumen Z-Score / Absolute Size Natural History & Remodeling Trajectory Chronic Antithrombotic Regimen (AHA 2017 / 2024 Update)
No Involvement Always Z < 2.0 Normal coronary architecture Low-dose Aspirin (3–5 mg/kg/d) for 4–6 weeks, then discontinue
Dilation Only Z 2.0 to < 2.5 (or decrease in Z >=1.0 during follow-up) Resolves completely within 4–8 weeks in >95% Low-dose Aspirin (3–5 mg/kg/d) for 6–8 weeks until lumina normalize
Small Aneurysm Z >= 2.5 to < 5.0 80–90% regress to normal luminal diameter within 1–2 years Low-dose Aspirin (3–5 mg/kg/d) until regression documented
Medium Aneurysm Z >= 5.0 to < 10.0, AND absolute dimension < 8 mm ~50% luminal “regression” (via intimal myofibroblastic filling; vessel wall remains stiff/calcified with impaired vasoreactivity) Low-dose Aspirin + Second Antiplatelet (Clopidogrel 0.2–1.0 mg/kg/d) (DAPT) while persistent
Large or Giant Aneurysm Z >= 10.0, OR absolute dimension >= 8 mm Never truly regress; sluggish turbulent flow (low shear stress) causes high risk of occlusive thrombosis, distal stenosis, and MI Low-Dose Aspirin PLUS Therapeutic Anticoagulation: Warfarin (INR 2.0–3.0), LMWH (Anti-Xa 0.5–1.0 U/mL), or DOAC (Rivaroxaban/Apixaban per AHA 2024 Update) (+ consider Triple Therapy [+ Clopidogrel] and Statin in highest-risk giant aneurysms)
  • Acute Non-Coronary Sequelae (Pancarditis):
    • Acute Kawasaki Myocarditis and Kawasaki Disease Shock Syndrome (KDSS): Subclinical myocarditis (interstitial edema and inflammatory infiltrate without myocyte necrosis) occurs in 50 to 70 percent of patients during the first week (manifesting as gallop rhythm, sinus tachycardia out of proportion to fever, mild troponin/NT-proBNP elevation, and depressed LV strain/EF), while 5 percent present with severe Kawasaki Disease Shock Syndrome (KDSS) (hypotension/cardiogenic shock with higher IVIG resistance and CAA risk, overlapping clinically with pediatric MIS-C). Unlike viral myocarditis, KD myocarditis recovers rapidly within 24 to 48 hours of IVIG administration.
    • Valvulitis (10 to 25 Percent): Acute transient Mitral Regurgitation (from papillary muscle dysfunction or leaflet valvulitis) or mild aortic regurgitation (whereas late mitral regurgitation results from ischemic papillary muscle infarction).
    • Pericarditis (15 to 25 Percent): Small acute pericardial effusion (rarely tamponade unless a giant CAA ruptures).
    • Electrical and Arrhythmic Sequelae: Prolonged PR interval (First-degree AV block), QT dispersion, and flattened T waves in the acute phase; Ventricular Tachycardia (VT), Ventricular Fibrillation (VF), and Sudden Cardiac Death resulting from acute occlusive coronary aneurysm thrombosis or chronic ischemic myocardial scar.

IIIACUTE ANTI-INFLAMMATORY MANAGEMENT (EXTINGUISHING CORONARY ARTERITIS)

  • Intravenous Immunoglobulin (IVIG — Class I, Level A): 2 g/kg administered as a single intravenous infusion over 10 to 12 hours, ideally initiated within the first 10 days of fever onset (and as early as diagnosed), or even after Day 10 if persistent fever, elevated CRP/ESR, or evolving coronary aneurysms are present. Reduces CAA incidence from 25 percent to <4 to 5 percent. (Defer live-attenuated viral vaccines [MMR, varicella] for 11 months after IVIG.)
  • Aspirin (Biphasic Dosing):
    • Acute Febrile Phase: Moderate-dose (30 to 50 mg/kg/day divided every 6 hours) or high-dose (80 to 100 mg/kg/day divided every 6 hours) oral Aspirin until the child is afebrile for 48 to 72 hours (note: Aspirin has zero independent effect on lowering CAA incidence compared to IVIG alone, so many centers prefer moderate 30–50 mg/kg/day dosing to reduce GI toxicity).
    • Subacute Phase: Transition to Low-Dose Antiplatelet Aspirin (3 to 5 mg/kg/day once daily) for 6 to 8 weeks (stopped if 6-to-8-week echocardiogram confirms normal coronaries). (Crucial Rule: Avoid concomitant Ibuprofen, which competitively blocks Aspirin’s irreversible acetylation of platelet COX-1, and ensure annual influenza vaccination to prevent Reye syndrome.)
    • Primary Adjunctive Intensification in High-Risk Acute KD (Baseline Z >=2.5 or Young Infants <6 Months — RAISE Trial / AHA 2024 Update): In children presenting upfront with coronary aneurysms (Z >=2.5) on baseline echocardiogram or at high risk of IVIG resistance, adding upfront Corticosteroids (RAISE Trial regimen: prednisolone 2 mg/kg/day for 2 to 3 weeks alongside initial IVIG) or Infliximab / Cyclosporine (KAICA Trial) significantly reduces CAA progression.
    • Salvage Therapy for IVIG-Resistant Kawasaki Disease (Occurs in 10 to 20 Percent): Defined as persistent or recrudescent fever (>=38.0 degrees C) at 36 hours or more after completion of the initial IVIG infusion:
    • Infliximab (10 mg/kg single IV infusion over 2 hours — KIDCARE Trial, Lancet Child Adolesc Health 2021): The randomized KIDCARE Trial proved that Infliximab resulted in shorter fever duration, shorter hospital stay, less hemolytic anemia, and reduced need for additional therapy compared with a second dose of IVIG.
    • Alternative Salvage Options: A second infusion of IVIG (2 g/kg) (with close monitoring for Coombs-positive isoagglutinin hemolytic anemia) or Corticosteroids (IV Methylprednisolone 2 mg/kg/day or pulse 30 mg/kg/day for 1–3 days followed by oral prednisone taper).

IVCHRONIC MANAGEMENT: THROMBOPROPHYLAXIS, ACUTE THROMBOSIS AND REVASCULARIZATION

  • Emergency Management of Acute Occlusive Giant Aneurysm Thrombosis (STEMI in a Child/Young Adult):
    • Challenge: Unlike adult atherosclerotic plaque rupture (where thrombus forms in a 3 mm vessel), thrombosis inside a 10 to 15 mm Giant Kawasaki Aneurysm involves a massive clot burden with stagnant eddy currents; standard adult primary PCI balloon angioplasty alone often causes distal embolization and no-reflow.
    • Treatment: Urgent Systemic or Intracoronary Thrombolysis (Alteplase [tPA] 0.5 mg/kg/h for 6 hours) + IV Unfractionated Heparin + Glycoprotein IIb/IIIa Inhibitor (Abciximab) or mechanical aspiration thrombectomy to dissolve the giant sac thrombus.
    • Elective Revascularization for Inducible Ischemia (Stress CMR / Stress Echo / PET Positive):
    • Coronary Artery Bypass Grafting (CABG) with Bilateral/Pedicled Internal Thoracic Artery (ITA / LIMA & RIMA) Grafts (Preferred in Children — Class I): Because pedicled Internal Mammary Artery (ITA) grafts grow somatically in length and diameter along with the growing child (yielding 20-to-25-year patency rates >85–90%, compared to <50% for saphenous vein grafts in children under 10 years), arterial CABG is preferred for multivessel disease, ostial/LMCA lesions, or long-segment stenoses at the inlet/outlet of giant aneurysms. (Note: Do not bypass a coronary vessel unless the proximal stenosis is critical [>=75–80% / FFR <=0.80], as competitive flow through a patent giant aneurysm causes string-sign graft occlusion.)
    • Percutaneous Coronary Intervention (PCI): Reserved for older adolescents/adults with focal single-vessel stenosis without giant aneurysm thrombosis; because chronic KD intimal lesions are densely fibrotic and heavily calcified, Rotational Atherectomy (Rotablator) or Intravascular Lithotripsy (IVL) with IVUS/OCT guidance is usually needed to prevent stent under-expansion or new neo-aneurysm formation (covered stents are used selectively to exclude non-branching aneurysms).

Key references

  • McCrindle BW, Rowley AH, Newburger JW, et al.: Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association, Circulation, 2017.
  • Jone PN, Tremoulet A, Choueiter N, et al.: Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association, Circulation, 2024.
  • Burns JC, Roberts SC, Tremoulet AH, et al. (KIDCARE Investigators): Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial, The Lancet Child & Adolescent Health, 2021.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.